You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
HalioDx operates a CLIA-certified lab through which OncoDNA will provide it molecular testing services to drugmakers studying precision cancer therapies.
The firm will use the proceeds for general corporate purposes and to possibly acquire or invest in complementary businesses and technology.
The proceeds of the bond are going to support the firm's operations as it awaits a final Medicare coverage decision on its colon cancer test.
The company said it intends to use the net proceeds from the offering to fund further commercialization of its clinical tests, among other uses.
The test, called LifeKit Prevent, analyzes microbial genomic biomarkers in stool samples that are strongly associated with specific stages of CRC progression.
Chia Tai Tianqing Pharmaceutical Group has agreed to copromote Genetron's HCCscreen test in hospitals where the pharma firm has an established presence.
The company said that part of the funding was an unsecured loan to support the analysis of tumor DNA using a nucleosome immunoprecipitation method.
Since the commercial launch of its technology last year, the firm has been validating it in studies with academic groups and pharmaceutical companies.
The changes follow a strategic review and are part of the company's previously announced plans for growing its revenues and reducing costs.
Hologic said that Biotheranostics' PCR-based gene expression tests have been validated in large studies in areas of oncology with high growth potential.
The researchers said this new data could lead to the development of effective therapies for patients with hereditary leiomyomatosis and renal cell carcinoma.
The companies said Tuesday that they are pursuing a clinical trial utilizing their respective liquid biopsy assays on clinical samples from lung cancer patients.
The firm reported preliminary revenues of $8.5 million for full-year 2020, which would beat the consensus Wall Street estimate of $8.0 million.
Over the next year or so, the investigators plan to sequence the genomes of 3,000 patients with cancer, heart disease, diabetes, or neurological disorders.
A multi-ancestry genome-wide association study meta-analysis uncovered 86 genetic loci associated with prostate cancer risk that researchers bundled into a genetic risk score.
Researchers used single-cell RNA sequencing to delve into intra-tumoral heterogeneity in peritoneal carcinomatosis, identifying a potential prognostic signature.
The combined solution will give health systems access to real-time genetics expertise so they can integrate genetic test results into patients' care.
Although the total number of deals went down in 2020, those deals were worth more compared to 2019 — four of the top five had billion-dollar price tags.
Early data around an initial composite assay showed it can predict immunooncology drug responses more accurately than tumor mutational burden.
AmoyDx will develop and seek regulatory approval in China for a lung cancer PCR panel to be used with Merck's MET inhibitor tepotinib.
Reuters reports that Germany is seeking to sequence 5 percent of patient samples that test positive for SARS-CoV-2.
23andMe and Medscape say primary care physicians are increasingly more comfortable with discussing direct-to-consumer genetic testing results.
The publisher of the Science family of journals will allow some authors to place peer-reviewed versions of their papers into publicly accessible repositories.
In Science this week: analysis of genome-wide association studies of chronic kidney disease, and more.